HDAC1 and neoplasm: Taken together, our findings establish SDFZ‐8 as a novel HDAC1 inhibitor that concurrently targets tumor cells and immune evasion mechanisms, providing a rational combinatorial strategy to enhance cancer immunotherapy efficacy.